Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with $275.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 21.65% to $275.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $706.0 million, a 38.98% decrease, with the full-year FY2025 number at $706.0 million, down 38.98% from a year prior.
  • Change in Acquisitions & Divestments was $275.0 million for Q4 2025 at Denali Therapeutics, up from $107.1 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $601.1 million in Q3 2023 to a low of $107.1 million in Q3 2025.
  • A 5-year average of $317.0 million and a median of $284.0 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 316.46% in 2023, then plummeted 67.06% in 2024.
  • Denali Therapeutics' Change in Acquisitions & Divestments stood at $193.8 million in 2021, then surged by 87.87% to $364.0 million in 2022, then soared by 34.34% to $489.0 million in 2023, then fell by 28.22% to $351.0 million in 2024, then fell by 21.65% to $275.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Change in Acquisitions & Divestments are $275.0 million (Q4 2025), $107.1 million (Q3 2025), and $162.2 million (Q2 2025).